Forte Capital LLC ADV Has $3.34 Million Stake in Johnson & Johnson (NYSE:JNJ)

Forte Capital LLC ADV trimmed its position in Johnson & Johnson (NYSE:JNJ) by 3.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 23,063 shares of the company’s stock after selling 854 shares during the period. Forte Capital LLC ADV’s holdings in Johnson & Johnson were worth $3,335,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. ING Groep NV increased its position in Johnson & Johnson by 58.5% during the 4th quarter. ING Groep NV now owns 524,810 shares of the company’s stock valued at $75,898,000 after purchasing an additional 193,689 shares during the period. Flossbach Von Storch SE boosted its position in Johnson & Johnson by 0.4% during the fourth quarter. Flossbach Von Storch SE now owns 6,529,296 shares of the company’s stock worth $944,267,000 after purchasing an additional 28,814 shares during the period. Morningstar Investment Management LLC boosted its position in shares of Johnson & Johnson by 5.5% in the fourth quarter. Morningstar Investment Management LLC now owns 5,855 shares of the company’s stock valued at $847,000 after acquiring an additional 303 shares during the period. First Bank & Trust bought a new stake in Johnson & Johnson during the fourth quarter valued at approximately $936,000. Finally, Hardy Reed LLC raised its stake in shares of Johnson & Johnson by 3.9% during the fourth quarter. Hardy Reed LLC now owns 12,901 shares of the company’s stock worth $1,866,000 after acquiring an additional 488 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on JNJ shares. Stifel Nicolaus cut their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Barclays increased their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Citigroup lowered their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Finally, Guggenheim increased their target price on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research report on Monday, February 3rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Price Performance

Shares of JNJ opened at $162.35 on Monday. The firm has a market cap of $390.87 billion, a price-to-earnings ratio of 24.41, a PEG ratio of 2.56 and a beta of 0.52. The stock has a 50 day moving average of $148.93 and a 200-day moving average of $155.86. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the company posted $2.29 EPS. The company’s revenue was up 5.3% compared to the same quarter last year. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.06%. Johnson & Johnson’s dividend payout ratio is 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.